Doctors Hospital Health System Limited Interim report Quarter ended July 31, 2023

Chairman's Report Doctors Hospital Health System Limited

Dear Shareholder,

On behalf of the Board of Directors of Doctors Hospital Health System, I report on your company's financial results for the six months ended July 31, 2023.

Consolidated net profit for the six months was \$6,687,081 compared to a profit of \$3,765,362 for the comparable period in fiscal 2023. Consolidated net patient services revenue increased \$11,937,694 or 25.57% over the 2nd quarter last year. The surge in revenue is indicative of the continuing rebounding of outpatient activity combined with a decline in inpatient days. Total inpatient days for the 6 months ended July 31, 2023 was 4,596 days, a decrease of 13.8% for the comparable period last year. While inpatient days for DHB declined, revenue from outpatient services rose by \$6,232,802 to \$36,144,375 for the six months ended July 31, 2023. Also of note is the significant decline in COVID-19 revenues totaling \$3,873,093, a 97.8% drop for the comparable period last year.

Consolidated expenses increased by \$9,370,938 or 20.67% over the comparable period last year. Notable increases in consolidated expenses were incurred in the following:

- Bad debt expense (\$3.2 million or 413.0%) the Group increased its loss rates on its portfolio of receivables at the end of fiscal year 2023 which is reflected in the increase in the provision for doubtful accounts in the current fiscal year when compared to the prior fiscal year.
- Salaries & benefits (\$3.9 million or 20.1%) as the Group expanded its operations into outpatient services in several locations, the associate headcount increased by 117, resulting in the significant increase in this expense.
- Medical services (\$1.6 million or 33.0%) there is a direct correlation of the increase in this expense with the expansion in outpatient facilities and the increase in revenues.
- Outside services (\$1.1 million or 26.9%) the Group incurred consulting services' fees (\$2 million) relating to the launch of our new software at the beginning of the fiscal year, which is a non-recurring expense.

There have been declines in other variable expenses, primarily medical supplies (\$2.0 million or 34.2%). The decrease in this expense is a result of adjustments made to medical supplies inventory during this fiscal year, combined with the increased utilization of supplies due to the additional outpatient locations.

Return on sales (net income margin) increased to 10.9% for the six months ended July 31, 2023, an increase of 77.6% compared to the same period last year of 7.7%, reflecting an improvement in efficiency.

The Board and Management team thanks you, our valued shareholders, Physicians, and all Associates for your continued support and loyalty to the Hospital.

We look forward to continuing to provide an excellent customer experience to our patients and visitors whose loyalty we also appreciate and value.

Felix Stubbs Chairman October 2, 2023

Consolidated Statement of Financial Position

July 31, 2023 with comparative figures at January 31, 2023 (Expressed in thousands of Bahamian dollars)

	July 31, 2023		January 31, 2023	
Assets				
Current assets:				
Cash and cash equivalents	\$	1,115	18,172	
Accounts receivable—patients, net (note 2)	+	12,344	13,653	
Accounts receivable—third party payors, net (note 2)		37,750	23,793	
Inventories		8,338	5,405	
Prepaid expenses & other assets		6,418	6,732	
		65,965	67,755	
Non-current assets:			01,100	
Investments – fixed income		6,762	6,878	
Investments		30	30	
Goodwill, net		431	431	
Other intangible assets		257	266	
Property, plant and equipment		56,510	43,353	
Right of use assets		2,852	3,469	
Right of use assets		66,842	54,427	
	Φ	,		
Total assets	\$	132,807	122,182	
Current liabilities: Accounts payable and other liabilities Lease liabilities, current portion Long-term debt, current portion	\$	27,057 1,061 254	22,444 1,173 249	
		28,372	23,866	
T . 11111.1				
Long-term liabilities:		2 0 2 2	2 502	
Lease liabilities		2,022	2,503	
Long-term debt		2,868	2,955	
		4,890	5,458	
Total liabilities		33,262	29,324	
 Shareholders' equity: Share capital: Authorized 12,500,000 common shares at par value of B\$0.04 each (January 31, 2023 – 12,500,000 shares Issued and fully paid 11,971,634 shares 	.)			
(January 31, $2023 - 11,971,634$ shares)		479	479	
Contributed surplus		25,778	25,778	
Retained earnings		25,778 73,288	23,778 66,601	
Retained carnings				
Total liabilities and shareholders' arrity	¢	<u>99,545</u> 132,807	92,858	
Total liabilities and shareholders' equity	\$	132,807	122,182	

Consolidated Statement of Comprehensive Income

Three months ended July 31, 2023 with comparative figures for the three months ended July 31, 2022 (Expressed in thousands of Bahamian dollars)

		ly 31, 2023	July 31, 2022	
Revenues				
Patient service revenue, net	\$	28,514	23,239	
Other		1,303	1,144	
Total revenues		29,817	24,383	
Expenses				
Salaries and benefits		12,002	9,724	
Medical supplies		2,833	2,601	
Medical services		3,406	2,482	
Bad debt expense, net of recoveries		1,491	211	
Depreciation and amortization		1,113	1,016	
Other operating		1,898	1,400	
Utilities		751	496	
Government taxes and fees		661	664	
Outside services		1,643	2,752	
Insurance		517	403	
Repairs and maintenance		606	487	
Rent		85	110	
Dietary expenses		278	122	
Legal expenses		18	36	
Interest expense		78	76	
Total expenses		27,380	22,580	
Net income & total comprehensive				
income for the period	\$	2,437	1,803	
Earnings per common share (expressed in Bahamian dollars):				
Basic and fully diluted	\$	0.20	0.15	

Consolidated Statement of Comprehensive Income

Six months ended July 31, 2022 with comparative figures for the six months ended July 31, 2021 (Expressed in thousands of Bahamian dollars)

	July 31, 2023	July 31, 2022
Revenues		
Patient service revenue, net	\$ 58,622	46,684
Other	2,773	2,418
Total revenues	61,395	49,102
Expenses		
Salaries and benefits	23,374	19,469
Medical supplies	3,898	5,923
Medical services	6,586	4,951
Bad debt expense, net of recoveries	4,030	786
Depreciation and amortization	2,233	2,013
Other operating	3,278	3,006
Utilities	1,446	926
Government taxes and fees	1,521	1,499
Outside services	5,329	4,199
Insurance	1,032	778
Repairs and maintenance	1,018	1,029
Rent	186	157
Dietary expenses	494	269
Legal expenses	120	174
Interest expense	163	158
Total expenses	54,708	45,337
Net income & total comprehensive		
income for the period	\$ 6,687	3,765
Return on sales (net income margin)	10.9%	7.7%
Earnings per common share (expressed in Bahamian dollars): Basic and fully diluted	\$ 0.56	0.31

Consolidated Statement of Changes in Equity

Six months ended July 31, 2023 (Expressed in thousands of Bahamian dollars)

	Number of shares	Share capital	Contributed surplus	Retained earnings	Total
Balance at January 31, 2023	11,971,634	\$ 479	\$ 25,778	\$ 66,601	\$ 92,858
Net income for the period	-	_	-	6,687	6,687
Dividends paid	-	_	_	_	-
Balance at July 31, 2023	11,971,634	\$ 479	\$ 25,778	\$ 73,288	\$ 99,545

Consolidated Statement of Cash Flows

Six months ended July 31, 2023 with comparative figures for the six months ended July 31, 2022 (Expressed in thousands of Bahamian dollars)

	July 31, 2023	July 31, 2022	
CASH FLOWS FROM OPERATING ACTIVITIES:			
Net income	\$ 6,687	3,765	
Adjustments to reconcile net income to net cash	\$ 0,007	0,700	
provided by operating activities:			
Depreciation and amortization	2,233	2,013	
Provision for doubtful accounts	4,030	786	
Operating income before working capital changes	12,950	6,564	
(Increase)/decrease in accounts receivable	(16,678)	18,361	
(Increase)/decrease in inventories	(2,933)	3,068	
Decrease/(increase) in prepaid expenses and other assets	314	(6,388	
Increase in accounts payable and other liabilities	4,613	526	
Net cash (used in)/from operating activities	(1,734)	22,131	
CASH FLOWS FROM INVESTING ACTIVITIES:			
Purchase of property, plant and equipment, net	(14,759)	(11,864	
Purchase of intangible assets, net	(5)	(100	
Maturity of investments, net	116	12,966	
Net cash from/(used in) investing activities	(14,648)	1,002	
CASH FLOWS FROM FINANCING ACTIVITIES:			
Repayment of long-term debt	(82)	(118	
Lease liabilities, net	(593)	948	
Dividends paid to shareholders	· -	(837	
Net cash used in financing activities	(675)	(7	
(Decrease)/increase in cash and cash equivalents	(17,057)	23,126	
Cash and cash equivalents at beginning of period	18,172	6,760	
Cash and cash equivalents at end of period	\$ 1,115	29,886	

Cash and cash equivalents comprise cash at bank and in hand, and short-term deposits with an original maturity of three months or less.

Notes to Interim Consolidated Financial Statements

Six months ended July 31, 2023

1. Significant accounting policies

These interim financial statements have been prepared in accordance with International Accounting Standard No. 34, Interim Financial Reporting; using the same accounting policies applied in the January 31, 2023 audited consolidated financial statements.

2. Accounts receivable

Accounts receivable are stated net of provisions for doubtful accounts of \$6.04 million.